Catabasis Pharmaceuticals, Inc. (CATB) EPS Estimated At $-0.23; Gardner Lewis Asset Management LP Has Lifted By $357,368 Its Humana (HUM) Position

May 2, 2018 - By Hazel Jackson

Humana Inc. (NYSE:HUM) Logo

Gardner Lewis Asset Management LP increased Humana Inc. (HUM) stake by 2.8% reported in 2017Q4 SEC filing. Gardner Lewis Asset Management LP acquired 1,441 shares as Humana Inc. (HUM)’s stock rose 9.24%. The Gardner Lewis Asset Management LP holds 52,894 shares with $13.12M value, up from 51,453 last quarter. Humana Inc. now has $39.87B valuation. The stock decreased 2.20% or $6.48 during the last trading session, reaching $288.71. About 227,279 shares traded. Humana Inc. (NYSE:HUM) has risen 31.54% since May 2, 2017 and is uptrending. It has outperformed by 19.99% the S&P500.

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.23 EPS on May, 10.They anticipate $0.18 EPS change or 43.90% from last quarter’s $-0.41 EPS. After having $-0.24 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see -4.17% EPS growth. The stock decreased 1.19% or $0.019 during the last trading session, reaching $1.581. About 15,445 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since May 2, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

Since December 15, 2017, it had 0 buys, and 10 selling transactions for $20.82 million activity. Another trade for 7,054 shares valued at $1.75 million was sold by BILNEY JODY L. $340,034 worth of Humana Inc. (NYSE:HUM) was sold by Huval Timothy S. on Friday, December 15. 14,075 shares were sold by BROUSSARD BRUCE D, worth $3.86 million. Christopher M Todoroff sold 16,389 shares worth $4.48 million. On Saturday, February 24 LeClaire Brian P. sold $3.49M worth of Humana Inc. (NYSE:HUM) or 12,719 shares. MARGULIS HEIDI S sold 3,727 shares worth $1.03M. 1,073 Humana Inc. (NYSE:HUM) shares with value of $295,450 were sold by Fleming William Kevin.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.16, from 1.21 in 2017Q3. It turned negative, as 40 investors sold HUM shares while 209 reduced holdings. 69 funds opened positions while 193 raised stakes. 125.53 million shares or 4.46% less from 131.39 million shares in 2017Q3 were reported. 25 were accumulated by Tci Wealth Advsr Inc. The Switzerland-based Swiss Natl Bank has invested 0.16% in Humana Inc. (NYSE:HUM). Partner Invest Management Lp has 1.79% invested in Humana Inc. (NYSE:HUM). Drw Securities Ltd Limited Liability Company has 0.05% invested in Humana Inc. (NYSE:HUM). Bluefin Trading invested in 0.46% or 30,405 shares. The Germany-based Deutsche Bancorp Ag has invested 0.07% in Humana Inc. (NYSE:HUM). M&T Financial Bank Corp holds 0.01% in Humana Inc. (NYSE:HUM) or 10,984 shares. Equitec Proprietary Mkts Limited Liability Corp stated it has 1.65% of its portfolio in Humana Inc. (NYSE:HUM). Canada Pension Plan Investment Board holds 343,392 shares or 0.16% of its portfolio. Robeco Institutional Asset Mngmt Bv has invested 0.26% in Humana Inc. (NYSE:HUM). Teacher Retirement System Of Texas holds 186,856 shares. Price Capital Mngmt reported 6,253 shares. Moreover, Employees Retirement System Of Texas has 0.13% invested in Humana Inc. (NYSE:HUM) for 43,000 shares. Bank Of New York Mellon Corporation has invested 0.11% in Humana Inc. (NYSE:HUM). Evercore Wealth Limited Liability Corporation stated it has 0% of its portfolio in Humana Inc. (NYSE:HUM).

Among 23 analysts covering Humana (NYSE:HUM), 15 have Buy rating, 0 Sell and 8 Hold. Therefore 65% are positive. Humana had 80 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Thursday, August 4 by Barclays Capital. IBC maintained the shares of HUM in report on Friday, March 31 with “Outperform” rating. The company was upgraded on Thursday, February 8 by Credit Suisse. The firm has “Equal Weight” rating by Barclays Capital given on Thursday, July 30. Piper Jaffray maintained the shares of HUM in report on Wednesday, February 7 with “Buy” rating. Leerink Swann maintained the stock with “Buy” rating in Thursday, February 8 report. Jefferies maintained Humana Inc. (NYSE:HUM) rating on Thursday, April 12. Jefferies has “Buy” rating and $35600 target. Oppenheimer maintained Humana Inc. (NYSE:HUM) on Thursday, March 30 with “Outperform” rating. The firm has “Buy” rating given on Monday, November 27 by Leerink Swann. The rating was initiated by Credit Suisse on Wednesday, December 16 with “Neutral”.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $45.91 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Humana Inc. (NYSE:HUM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: